Key facts
- This page summarizes Simon May's Form 3 filing for BIO-RAD LABORATORIES, INC. (BIO).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 07 Jan 2022, 12:09.
Simon May - 04 Jan 2022 Form 3 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)
- Reporting relationship
- EVP, President, LSG
- Issuer ticker
- BIO
- Reported as of
- 04 Jan 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 07 Jan 2022, 12:09:06 UTC
- Next SEC filing
- 06 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Simon May
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Simon May filed Form 3 for BIO-RAD LABORATORIES, INC. (BIO) on 07 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIO
holding
Bio-Rad A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 43
- Date
- 04 Jan 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIO
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Jan 2022
- Ownership
- Direct
- Underlying class
- Bio-Rad A Common Stock
- Underlying amount
- 600
- Exercise price
- $0.000000
- Footnotes
- F1, F6
BIO
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Jan 2022
- Ownership
- Direct
- Underlying class
- Bio-Rad A Common Stock
- Underlying amount
- 1,200
- Exercise price
- $0.000000
- Footnotes
- F2, F6
BIO
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Jan 2022
- Ownership
- Direct
- Underlying class
- Bio-Rad A Common Stock
- Underlying amount
- 1,578
- Exercise price
- $0.000000
- Footnotes
- F3, F6
BIO
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Jan 2022
- Ownership
- Direct
- Underlying class
- Bio-Rad A Common Stock
- Underlying amount
- 1,228
- Exercise price
- $0.000000
- Footnotes
- F4, F6
BIO
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 04 Jan 2022
- Ownership
- Direct
- Underlying class
- Bio-Rad A Common Stock
- Underlying amount
- 1,486
- Exercise price
- $0.000000
- Footnotes
- F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
On September 5, 2017, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.
Footnote F2
On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.
Footnote F3
On September 3, 2019, the reporting person was granted 2,629 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.
Footnote F4
On September 2, 2020, the reporting person was granted 1,637 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Footnote F5
On September 1, 2021, the reporting person was granted 1,486 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Footnote F6
Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.